Hebron Technology Co., Ltd. — FY2017 Form 20-F Summary
Entity and period: The supplied filing is Hebron Technology Co., Ltd.’s annual report for the fiscal year ended December 31, 2017, filed April 25, 2018. It does not identify AIOS Tech Inc. as the registrant, and it reports annual—not quarterly—results.
Business context
Hebron is a British Virgin Islands holding company whose operating subsidiaries are based in China. It manufactures fluid-control equipment, including valves and pipe fittings, and provides customized installation services, primarily for pharmaceutical and other clean-industry customers. Installation services generated 81% of FY2017 revenue; fluid-equipment sales generated 19%. Approximately 99% of revenue came from the PRC. The audited consolidated financial statements were prepared under U.S. GAAP.
Key financial metrics
| Metric | FY2017 | FY2016 |
|---|---|---|
| Revenue | $29.20 million | $27.10 million |
| Gross profit / gross margin | $10.44 million / 35.8% | $10.46 million / 38.6% |
| Operating income / operating margin | $3.88 million / 13.3% | $7.98 million / 29.5% |
| Net income / net margin | $7.14 million / 24.4% | $5.93 million / 21.9% |
| Operating cash flow | $(6.10) million | $1.58 million |
| Cash and cash equivalents at year-end | $3.22 million | $11.88 million |
| Current assets / current liabilities | $38.58 million / $13.19 million | $34.58 million / $15.40 million |
| Working capital | $25.39 million | $19.18 million |
| Total liabilities | $14.02 million | $15.93 million |
FY2017 bank loans were $872,852. The company also reported $590,865 of financing liability from a machinery sale-leaseback, including $179,182 current and $411,683 long-term. Total shareholders’ equity was $40.53 million. Basic and diluted earnings per share were both $0.49.
Changes versus FY2016
- Revenue increased 8%, but gross profit was essentially flat as cost of revenue rose 13%. Gross margin declined from 38.6% to 35.8%.
- Installation revenue fell about 2% to $23.75 million, while equipment-sales revenue rose 95% to $5.45 million.
- Operating income declined 51%, primarily alongside a sharp increase in operating expenses: general and administrative expense rose to $3.87 million from $705,038, and R&D expense rose to $508,282 from $33,847. Management attributed the G&A increase in part to technology and M&A consulting, higher bad-debt expense, listing costs, and overseas exhibitions.
- Net income increased 20% despite lower pretax income, principally because of a $4.975 million tax recovery associated with reversal of previously accrued tax liabilities. This makes FY2017 net income less representative of underlying operating performance.
- Operating cash flow turned negative, primarily due to increases in receivables and supplier/subcontractor advances, alongside lower tax payable and deferred revenue. Cash fell by $8.66 million during the year.
Outlook, risks, contingencies, and unusual items
- Outlook: The filing gives no quantified earnings or revenue guidance. Management expected to fund operations through operating cash flows and existing cash, and said these sources, with possible access to loans or related-party support, should meet needs beyond 12 months. Plans included expanding equipment sales, repair and maintenance services, R&D, and regional service capacity. The intelligent process-control valve remained in trial use; broad commercial sales were not yet established.
- Tax uncertainty: Taxes payable were $7.07 million at year-end, largely unpaid income and business taxes. The company had made no tax payments since 2015 and was discussing settlement with the local tax authority. Management estimated potential interest and penalties of nil to $0.83 million, not accrued. PRC tax examination years 2015–2017 remained open. The reversal of approximately $5.0 million of prior tax accruals was based on a local tax authority statement concerning periods through 2014; the final settlement remained uncertain.
- Customer and collection concentration: Four customers represented approximately 66% of 2017 revenue. Two general contractors accounted for all reported year-end contract receivables; net contract receivables were $16.90 million. Receivable days increased to 196 from 145. Management reported no allowance against contract receivables, relying on customer credit history and collection expectations.
- Supplier advances and cash conversion: Net prepayments and advances to suppliers reached $11.90 million, up from $4.54 million, and included a $692,635 allowance for doubtful accounts. Cash was held in uninsured PRC bank accounts and was subject to currency-conversion and remittance controls.
- Governance and controls: Management concluded disclosure controls and internal control over financial reporting were ineffective because accounting personnel lacked sufficient U.S. GAAP and SEC-reporting expertise. The auditor gave an unmodified opinion on the financial statements but did not audit or opine on internal-control effectiveness.
- Other exposures: Raw-material costs, competition, subcontractor concentration, product-liability claims, and reliance on management-owned intellectual property are identified risks. No warranty reserve was recorded. A possible RMB 0.15 million payment to Zhejiang University was considered not yet due, conditional on sales of the jointly developed product. No material legal proceedings or material off-balance-sheet arrangements were reported.
- Post-period developments: In March 2018 the company adopted a dual-class share structure, with Class B shares carrying five votes each; the CEO controlled the Class B shares. In April 2018 it completed a 49% acquisition of Weijia Bio-Tech for 1,442,778 unregistered Class A shares. These events occurred after FY2017 and are not reflected in year-end financial results.
Most important facts for investors to verify
- Reconcile the $7.07 million year-end tax payable with the filing’s descriptions of approximately $12.0 million of accrued tax liabilities before reversal, the $4.975 million tax recovery, and the possible $0.83 million penalty exposure.
- Check subsequent collections of the $16.90 million contract receivable balance and recoverability of the $11.90 million in supplier advances and prepayments.
- Assess whether negative operating cash flow, lower cash balances, and upcoming debt and lease payments are consistent with management’s liquidity expectations.
- Confirm remediation progress for the disclosed material weakness in U.S. GAAP and SEC-reporting expertise, and monitor any further control findings.
- Review the commercial progress and economics of equipment sales and the trial-stage intelligent valve, and the results and dilution implications of the Weijia Bio-Tech acquisition.
- Reconcile the filing’s foreign-currency disclosures: the audited statements show a $2.25 million translation gain in 2017, while some narrative text describes a translation loss of approximately $2.2 million.